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Abstract 
Squamous cell carcinoma (SCC) is the second most common human skin cancer and the second leading 
cause of skin cancer-related death. Recently, a new compound, ingenol mebutate (IM), was approved for 
treatment of actinic keratosis (AK), a precursor of SCC. Since the mechanism of action is poorly 
understood, we have further investigated the mechanism of IM-induced cell death. 
We elucidate direct effects of IM on primary keratinocytes, patient-derived SCC cells and a SCC cell line. 
Transcriptional profiling followed by pathway analysis was performed on IM-treated primary keratinocytes 
and patient-derived SCC cells to find key mediators and identify the mechanism of action. Activation of the 
resulting pathways was confirmed in cells and human skin explants and supported by a phosphorylation 
screen of treated primary cells. The necessity of these pathways was demonstrated by inhibition of certain 
pathway components. 
IM inhibited viability and proliferation of all keratinocyte-derived cells in a biphasic manner. Transcriptional 
profiling identified the involvement of PKC/MEK/ERK signaling in the mechanism of action and inhibition of 
this signaling pathway rescued IM-induced cell death after treatment with 100 nM IM, the optimal 
concentration for the first peak of response. We found the interleukin decoy receptors IL1R2 and IL13RA2 
induced by IM in a PKC/MEK/ERK-dependent manner. Furthermore, siRNA knock-down of IL1R2 and 
IL13RA2 partially rescued IM-treated cells. 
In conclusion, we have shown that IM-induced cell death is mediated through the PKCδ/MEK/ERK 
pathway, and we have functionally linked the downstream induction of IL1R2 and IL13RA2 expression to 
the reduced viability of IM-treated cells. 
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Introduction 
Actinic keratoses (AKs) are hyperkeratotic lesions on sun-exposed surfaces such as the face, scalp and 
lower arms. AKs are caused by accumulated UV exposure over lifetime and develop from atypically 
proliferating keratinocytes (1). In about 8% of cases, AKs can progress to invasive SCCs (2), the second 
most common form of skin cancer, and therefore need to be treated. About 50% of SCCs harbor p53 
mutations, some of them with the typical UV signature of cyclobutane pyrimidine dimers (3). The risk for 
organ transplant recipients to develop SCC is highly increased due to their treatment with 
immunosuppressive drugs (4) such as azathioprine, a photosensitizer to UVA light (5) or cyclosporine A 
inducing the protumorigenic transcription factor ATF3 (6, 7). The incidence of SCC in the general 
population continues to increase with high morbidity and low mortality (8). In contrast to basal cell 
carcinoma (BCC), SCC carries a risk of metastasis. The current treatment options for actinic keratosis 
range from topical treatments with gels or creams for field cancerization to cryotherapy for single lesions 
(9), whereas SCC is normally treated by surgical excision. Self-directed treatments are preferred by 
patients, but are time consuming as they need to be applied for weeks or months to produce clinical 
results. 
 
Recently a new compound, ingenol mebutate (IM), was registered in the USA and Europe for topical 
treatment of AK in two different concentrations depending on the treatment location. IM showed 42.2% 
complete clinical clearance compared to placebo (10) and has the great advantage of a short treatment 
duration (i.e. two to three consecutive days), a short period of local skin reaction and no systemic adverse 
events (11, 12). Although IM is registered and used in the clinic, its exact mechanism of action is not fully 
understood. Recent studies suggest a dual mechanism of action with rapid initial necrosis (13) followed by 
activation of the innate immune system (14). Although several reports investigated the mechanism of 
action of IM on different cancer cell lines like colon cancer (15), melanoma (16) and leukemia (17), there is 
only one report studying the effect on epithelial cells (18). In that paper, the authors demonstrate acute 
cytotoxicity of clinical drug concentrations on cancer cell lines and keratinocytes with disruption of the 
mitochondrial network and the involvement of intracellular calcium release. 
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To better characterize the mechanism of action of IM in epithelial cells, we analyzed the impact of IM on 
the proliferation and viability of primary keratinocytes, primary patient-derived SCC cells and a SCC cell 
line. Furthermore, we identified signaling pathways essential for IM action by gene expression analysis 
and confirmed their contribution in primary cell cultures and human skin explants. We functionally 
demonstrated the critical importance of several novel genes using functional in vitro assays. 
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Materials and Methods 
 
Cell culture and skin explants 
The human SCC12 cell line (19) was cultured in Keratinocyte-SFM supplemented with L-glutamine, EGF 
and BPE (Gibco, Basel, Switzerland). The human SCC13 cell line (19) was cultured in DMEM (Gibco) with 
10% fetal calf serum (FCS). Both cell lines were obtained from Gian-Paolo Dotto (University of Lausanne) 
in 2011 and were not further tested. Human primary keratinocytes and fibroblasts were isolated from 
healthy human skin. Human fibroblasts and melanoma cells were cultured in RPMI 1640 (Sigma, Buchs, 
Switzerland) with 10% FCS. Melanoma cells were isolated from biopsies taken from consenting patients. 
Normal skin samples were obtained from abdominal and mammary surgery. Human primary SCC cells 
were isolated from punch biopsies taken from SCC surgical excisions. Both healthy skin and SCC 
biopsies were also used as whole explants for experiments. Primary cells were cultured in CnT-07 
medium (CellNTec, Bern, Switzerland). All cells were cultured at 37°C and 5% CO2. 
Institutional board approval for the use of human tissue was granted; all donors signed written informed 
consent forms in accordance with the Code of Ethics of the World Medical Association (Declaration of 
Helsinki) for experiments involving humans (ethical approval number EK647). All samples were obtained 
from the University Hospital Zurich. 
 
Viability and proliferation assay 
Cells were seeded on 24- or 96-well plates at 50% confluence and treated for 24h with IM or DMSO, 
respectively. When indicated, IM and DMSO were combined with specific kinase inhibitors. Viability was 
analyzed by MTT assay (Sigma). Proliferation was assessed by BrdU incorporation using the BrdU assay 
kit (Merck Millipore, Darmstadt, Germany). 
 
Gene expression array and analysis 
Gene expression was analyzed in normal keratinocytes and patient-derived SCC cells 24h after IM or 
control treatment. RNA was isolated and cDNA was generated. The SurePrint G3 Human GE v2 8x60K 
Microarray (Agilent, Santa Clara, CA, United States) was used to analyze the samples.  
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Raw data was processed in the programming environment R using the limma package (20). The data 
were background corrected and quantile normalized. Pairwise comparison of treatment vs control samples 
was performed for each cell line. Differentially expressed genes were deemed to be significant if the 
absolute log-fold change was more than 2 and the FDR adjusted p-value was less than 0.05. Heat map 
was generated by hierarchical clustering and Euclidean distance was used for distance metric. Microarray 
data have been deposited in NCBI’s Gene Expression Omnibus (21) in accordance with MIAME 
guidelines (GEO Series accession number GSE63308). Pathway analysis of deregulated genes was done 
using the software GeneGo (Thomson Reuters, Zug, Switzerland). 
 
RNA isolation and qPCR 
RNA from cells and tissue was isolated with TRIzol® (Invitrogen, Basel, Switzerland) as described in the 
protocol. Reverse transcription was achieved using the Reverse Transcription Kit from Promega (Madison, 
WI, United States). qPCR was performed on the ViiA7 real time PCR machine (life technologies, Zug, 
Switzerland) using SYBR green mix (Roche, Basel, Switzerland). The following primers from Microsynth 
(Balgach, Switzerland) were used. 
36B4 fwd: 5’-GCAATGTTGCCAGTGTCTGT-3’, 36B4 rev: 5’-GCCTTGACCTTTTCAGCAAG-3’ 
IL1R2 fwd: 5’-CAGCTTCTCTGGGGTCAAGA-3’, IL1R2 rev: 5’-CGTGGCCCCTCGGTCA-3’ 
IL13RA2 fwd: 5’-GCGGGGAGAGAGGCAATATC-3’, IL13RA2 rev: 5’-AGCATCCGATAGCCAAGCAA-3’ 
PKCδ fwd: 5’-CTGCAAGAAGAACAATGGCAAG-3’, PKCδ rev: 5’-ATCCACGTCCTCCAGGAAATACT-3’ 
DEFB4A fwd: 5’-TGGTGAAGCTCCCAGCCATC-3’, DEFB4A rev: 5’-
ATACCACCAAAAACACCTGGAAGA-3’ 
C15orf48: 5’-CCCACCAGGCGATCAATACT-3’, C15orf48 rev: 3’-AGGGAATGAGTTCCTTCCTTTTCA-3’ 
EGR1 fwd: 5’-ACCTGACCGCAGAGTCTTTT-3’, EGR1 rev: 5’-GAGTGGTTTGGCTGGGGTAA-3’ 
SPRY2 fwd: 5’-TGCACATCGCAGAAAGAAGAG-3’, SPRY2 rev: 5’-AGAACACATCTGAACTCCGTGA-3’ 
CFOS fwd: 5’-GGGGCAAGGTGGAACAGTTA-3’, CFOS rev: 5’-AGTTGGTCTGTCTCCGCTTG-3’ 
 
Protein detection 
Cells were lysed in RIPA buffer (Cell Signaling, Danvers, MA, United States, #9806) and protein extracts 
were analyzed by western blotting using the following antibodies: anti-pPKCδ T505 (#9374), anti-pPKCδ 
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Y311 (#2055), anti-PKCδ (#9616), anti-pPKCα/βII T638/641 (#9375), anti-PKCα (#2056) anti-pp42/44 
(#9101), anti-p42/44 (#9102), anti-pJNK (#9251), anti-JNK (#9252), anti-pp38 (#9211), anti-p38 (#9212), 
anti-rabbitHRP (#7074) all from Cell Signaling, anti-β-Actin (sc-47778, Santa Cruz Biotechnologies, 
Heidelberg, Germany), Rabbit anti-mouse IgG H&L HRP (ab6728). Proteins were detected by ECL on 
Hyperfilm (Amersham, GE Healthcare, Glattbrugg, Switzerland). 
 
Phosphoprotein array 
PathScan® Intracellular Signaling Array Kit from Cell Signaling (#7323) was used according to the 
manufacturer’s instructions. 
 
Drugs and inhibitors 
Ingenol mebutate (Suppl. Fig. 1A) was kindly provided by LEO Pharma A/S (Ballerup, Denmark). Ingenol 
mebutate was either dissolved in DMSO for cell culture treatment or suspended in commercial vehicle for 
treatment of organ cultures. Cells and organ cultures were treated with different drug concentrations for 
varying durations as indicated. For PKC inhibition, AEB071 (Selleckchem, Houston, TX, United States, 
S2791) was used at concentrations between 500 nM and 10 µM. The ERK inhibitor SCH772984 
(ChemScene, Monmouth Junction, NJ, United States, CS-1421) and the MEK inhibitor GSK1120212 
(Cellagen Technology, San Diego, United States, #C4112-5) (Suppl. Fig. 1B) were used at concentrations 
of 500 nM. The JNK inhibitor SP600125 (Santa Cruz, sc-200635) was used at 100-500 nM. The p38 
inhibitor SB203580 (Cell Signaling, #5633) was used at 250-500 nM. 12-O-Tetradecanoylphorbol-13-
acetate (TPA) (Sigma, #P1585) and used at various concentrations as indicated in the results section. 
 
Knock-down 
For knock down of PKCδ, IL1R2, and IL13RA2, cells were transfected with INTERFERin® (Polyplus 
transfections) and specific siRNAs (QIAgen, Hombrechtikon, Switzerland).  
siCtrl: target sequence 5’-AATTCTCCGAACGTGTCACGT-3’ 
siPKCα #3: target sequence 5’-CAAGACGTCTTTGGAATCCAA-3’ 
siPKCα #5: target sequence 5’-AACCATCCGCTCCACACTAAA -3’ 
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siPKCδ #1: target sequence 5’-CCGGGACACTATATTCCAGAA-3’ 
siPKCδ #7: target sequence 5’-AACTCTACCGTGCCACGTTTT-3’ 
siPKCδ #11: target sequence 5’-CAGCAGCAAGTGCAACATCAA-3’ 
siIL1R2 #2: target sequence 5’-CACGCCAGGAATATTCAGAAA-3’ 
siIL1R2 #4: target sequence 5’-AAGACTGACAATCCCGTGTAA -3’ 
siIL13RA2 #1: target sequence 5’-CAGGATATGGATTGCGTATAT-3’; 
siIL13RA2 #5: target sequence 5’-AAGGTGAAGACCTATCGAAGA-3’ 
Cells were incubated for 30h with the transfection mix before they were treated with the drug for 24h. 
Knock-down of each gene was confirmed (Suppl. Fig. 2). 
 
Immunohistochemistry  
After treatment samples were fixed in 4% formalin for 2 days, followed by dehydration and embedding in 
paraffin. Seven μm sections were made and stained with H&E or for pERK with the antibody pp42/44 (Cell 
Signaling, #9101).  
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Results 
 
Ingenol mebutate inhibits viability and proliferation of keratinocytes and SCC cells 
To investigate the impact of IM on epithelial cell viability and proliferation and to determine a working 
concentration for further experiments, we treated primary keratinocytes, patient-derived SCC cells, and 
SCC cell lines for 24h, 48h and 72h with IM in a range from 1 nM to 105 nM. All cell types showed a 
biphasic decrease in viability (Fig. 1A) and proliferation (Fig. 1B) upon drug treatment. Interestingly, all 
cells exhibited a drop in viability and proliferation around a concentration of 100 nM, while cells appeared 
healthier at lower (1-10 nM) and higher (103-104 nM) concentrations (Fig. 1A and 1B). At a concentration 
of 105 nM, cells died to a great extent due to cytotoxicity. For further experiments we used a concentration 
of 100 nM, since this concentration had the largest effect at the first peak of the biphasic response. 
 
To find out whether the biphasic effect was cell-type specific, we additionally treated fibroblasts and 
melanoma cells with similar concentrations of IM for 24h. We found no biphasic effect in fibroblasts, since 
they were resistant to the highest concentration used (105 nM). Melanoma cells did not show a biphasic 
effect either, since they were almost unaffected at low concentrations, whereas viability was 50% 
decreased at the highest concentration used in the experiment (105 nM) (Suppl. Fig. 3A). Furthermore, we 
analyzed the viability of the SCC13 cell line after 24h treatment with several concentrations of the tumor 
promoting tetradecanoyl phorbol acetate (TPA), a drug structurally related to the anti-cancer drug IM, both 
being phorbol esters and known potent PKC activators (22). This was done to investigate if the effect 
observed with IM was drug- specific. Unlike IM we did not detect any biphasic effect upon TPA treatment 
(Suppl. Fig. 3B). 
 
Gene expression analysis reveals involvement of PKC and MAPK signaling 
To identify genes and signaling pathways mediating IM activity, we performed gene expression analysis 
on primary keratinocytes and patient-derived SCC cells treated for 24h with either DMSO or different 
concentrations of IM (1 nM, 100 nM, 104 nM). In concordance with the results from the viability and 
proliferation assays, most genes were differentially expressed in the presence of 100 nM IM (Fig. 2A). 
Fewer changes were detected at a concentration of 104 nM while 1 nM of IM had almost no effect (Suppl. 
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Fig. 4A). At a concentration of 100 nM, we found 1227 genes upregulated in keratinocytes and 795 in 
SCC cells. 390 of these genes overlap between the two cell types. Furthermore, we found 1887 
downregulated genes in keratinocytes and 996 in SCC cells with 713 genes overlapping (Fig. 2B). 
Hierarchical clustering of the microarray data showed common clusters of gene expression patterns in the 
keratinocytes and SCC cells upon drug treatment, as compared to vehicle-treated cells. Pathway analysis 
of down-regulated genes using the software GeneGo identified mostly cell cycle-associated pathways and 
DNA damage repair pathways (Suppl. Fig. 4B). Upregulated genes following 100 nM IM treatment mostly 
affected pathways such as ERK1/2- and Protein Kinase C (PKC)-signaling in keratinocytes and ERK1/2 
signaling in SCC cells (Suppl. Fig. 4C). 
To identify key mediators of the IM effect, we took the top 5 upregulated genes in SCC cells that were also 
upregulated in keratinocytes. DEFB4A, ZP4, IL13RA2, CCL5, and IL1R2 were thus selected. We did not 
focus on C15orf48, which was also was among the top 5 upregulated genes, since we were interested in 
genes that are upregulated in both healthy and cancerous keratinocytes and C15orf48 was only found to 
be upregulated in SCC cells. Furthermore, we could not confirm the upregulation of C15orf48 in SCC 
tissue (data not shown). From literature research, we found DEFB4A, IL1R2 and IL13RA2 to be the most 
interesting ones. IL1R2 and IL13RA2 are decoy receptors that were thought to have no signaling function. 
However, a recent paper demonstrated a signaling ability of IL13RA2 (23). Additionally, IL13AR2 was 
reported to slow down or even prevent tumor growth in mice when overexpressed in pancreatic or breast 
cancer cells (24). Furthermore, IL1β was shown to enhance proliferation of oral keratinocytes (25) and 
therefore the upregulation of its decoy receptor by IM may play a crucial role in the mechanism of action of 
IM. DEFB4A was shown to be differentially expressed in SCC (26). We then confirmed the upregulation of 
these genes by qPCR in keratinocytes, patient-derived SCC cells, two SCC cell lines, human epidermis 
and human SCC explants after 24h of IM treatment. We found IL1R2 and IL13RA2 consistently and 
significantly upregulated in all tested cell types and explant tissues after treatment with IM, while DEFB4A 
upregulation could not be confirmed in SCC cell lines and SCC explants (Suppl. Fig. 4D, Suppl. Tab. 1). 
 
PKCδ plays a fundamental role in the mechanism of action of ingenol mebutate 
As our pathway analysis agreed with earlier studies (16, 22) that indicated a role for PKC signaling 
following IM exposure, we further investigated this pathway as a possible mechanism of action in the loss 
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of epithelial cell viability and proliferation. We incubated primary keratinocytes, patient-derived SCC cells 
and the SCC13 cell line with 100 nM IM for up to 45 minutes and found PKCδ to be highly phosphorylated 
in the hinge region (Y311) in all cell types while PKCα is not phosphorylated (Fig. 3A). Y311 was 
previously reported to be required for PKCδ activation and furthermore enhances autophosphorylation of 
PKCδ on T505 (27). Accordingly, we found the activation loop (T505) of PKCδ to be more phosphorylated 
in all three cell types after 24h drug treatment, whereas this phosphorylation could be blocked by the PKC 
inhibitor AEB071 (Fig. 3B). Although PKCδ can function without being phosphorylated at T505, this 
phosphorylation increases the catalytic activity of PKCδ (27). Furthermore, T505 phosphorylation 
influences the substrate specifity of PCKδ and is essential for the activation of the AP1 family of 
transcription factors (28). 
 
To further investigate the role of PKCδ, we used IM alone or in combination with the PKC inhibitor 
AEB071 and measured cell viability of primary keratinocytes, SCC patient cells and the SCC13 cell line 
after 24h of treatment. We found cell viability to be partially rescued by PKC inhibition when treated with 
IM (Fig. 3C). Since the PKC inhibitor is not entirely specific for single isoforms, we further validated the 
role of PKCδ using siRNA to knock-down PKCδ in SCC13 cells followed by analysis of cell viability after 
24h IM treatment. Similar to our findings with the PKC inhibitor, we detected a rescue of cell viability upon 
IM treatment when PKCδ was knocked down. A knock-down PKCα followed by IM treatment led only to a 
partial rescue, while PKCδ knock-down could rescue the IM-treated cells completely  (Fig. 3D). 
 
ERK is activated by ingenol mebutate treatment in a PKC-dependent manner and mediates IM-
dependent effects on cell viability 
Besides PKC signaling, our pathway analysis suggested ERK1/2 to be involved in mediating the effect of 
IM. To confirm this and to exclude other pathways involved in MAPK signaling (e.g. p38, JNK) we 
performed a phosphorylation array experiment with primary keratinocytes and SCC cells from three 
different donors and found ERK to be phosphorylated upon IM treatment, while other pathways of MAPK 
signaling (p38 and JNK) showed no or only weak phosphorylation (Suppl. Fig. 5A). Weak or nonexistent 
phosphorylation of JNK and p38 was further validated on cells from more donors by conventional western 
blotting (Fig. 4A). In order to test the effect of IM in a more natural model of skin, we treated human skin 
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explants in three independent experiments with either vehicle or IM gel 0.05%. Assessment of ERK 
phosphorylation after 24h of treatment revealed a sustained activation of ERK compared to vehicle-treated 
samples (Fig. 4B). To further demonstrate activation of ERK, we analyzed the expression of known ERK 
target genes (EGR1, SPRY2, CFOS) (29) in SCC13 cells, primary keratinocytes and patient-derived SCC 
cells after 24h of treatment by qPCR and found them to be upregulated upon IM treatment, while the 
upregulation of the ERK target genes was abolished by an ERK inhibitor (SCH772984) and a MEK 
inhibitor (GSK1120212B) (Suppl. Fig. 5B). Additionally, we used either the PKC inhibitor AEB071 or a 
knock-down of PKCδ, either alone or in combination with IM and analyzed the expression of ERK target 
genes. Either inhibition of PKC or knock-down of PKCδ could prevent the upregulation of ERK target gene 
expression after IM treatment (Fig. 4C). Furthermore, we analyzed the phosphorylation of ERK by western 
blotting after short-term IM treatment in cells treated with the PKC inhibitor and in cells with PKCδ knock-
down. The drug alone induced phosphorylation of ERK, which was blocked by addition of the PKC 
inhibitor (Fig. 4D, left panel) or by knock-down of PKCδ (Fig. 4D, right panel). This was confirmed in 
human skin explants pre-incubated in either DMSO or PKC inhibitor for 2h and treated with either vehicle 
or IM gel 0.015%. After 18h of incubation we analyzed pERK status by immunohistochemistry and found 
sustained ERK phosphorylation after drug treatment, while this phosphorylation was abolished by the PKC 
inhibitor (Fig. 4E). Taken together these results indicate that ERK is rapidly phosphorylated by IM in a 
PKC-dependent manner upon drug treatment. To further investigate these pathways in the mechanism of 
action of IM we analyzed the viability of primary keratinocytes, patient-derived SCC cells and the SCC13 
cell line after 24h treatment with either the drug alone or in combination with the ERK inhibitor 
(SCH772984) or the MEK inhibitor (GSK1120212B). As seen in previous experiments, cell viability 
dropped below 50% upon IM treatment. However, viability was partially rescued when cells were treated in 
combination with the MEK or ERK inhibitor but not in combination with the JNK inhibitor SP600125 or the 
p38 inhibitor SB203580 (Fig. 4F). 
 
IL1R2 and IL13RA2 partially mediate the mechanism of action of ingenol mebutate in SCC 
To further investigate the role of IL1R2 and IL13RA2, we first confirmed their upregulation upon 24h IM 
treatment in keratinocytes, patient-derived SCC cells, the SCC12 and SCC13 cell lines and epidermis 
from human explants by qPCR (Suppl. Fig. 4D). C15orf48 was not further investigated due to the lack of a 
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commercially available antibody and the fact that we could not confirm its upregulation in SCC tissue. 
Since we saw an upregulation of IL1R2 and IL13RA2 after 24h of treatment, we performed time course 
experiments in primary keratinocytes and epidermis from human skin explants to better define the 
timescale of gene regulation. We found both genes to be upregulated after 2-6h of treatment (Suppl. Fig. 
6). 
Furthermore we treated cells with IM alone or in combination with the PKC-, the MEK- or the ERK inhibitor 
respectively and found that the drug-dependent upregulation of both genes was partially abolished. IM in 
combination with JNK inhibition or p38 inhibition had almost no repressive effect on the expression of the 
two genes (Fig. 5A). Additionally we knocked down PKCδ by siRNA, which also prevented the drug-
dependent upregulation of IL1R2 and IL13RA2 mRNA (Fig. 5B). To find out whether IL1R2 or IL13RA2 
play an essential role in the mechanism of action IM, we knocked down these two genes with siRNA and 
analyzed cell viability upon drug treatment. Interestingly, both IL1R2 and IL13RA2 knock down partially 
rescued the viability of drug-treated SCC13 cells (Fig. 5C). 
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Discussion 
Ingenol mebutate (IM) is approved for the topical treatment of actinic keratosis (AK), the precursor of 
squamous cell carcinoma (SCC). However, its mechanism of action is not completely understood. Several 
studies investigated IM in the context of different cancers (15-17) and suggest a role of the innate immune 
system (14) but there is only one study that focuses on the effect on the actual target, the malignant 
keratinocytes (18). While that study used high IM concentrations (100-400 µM) and short incubation times, 
leading to cytotoxicity involving mitochondrial network disruption, we investigated the mechanism of action 
of IM in healthy keratinocytes, SCC cells and skin explants at lower concentrations (100 nM) and up to 
72h. We showed that IM induced a direct effect on viability and proliferation on cells of different origin. 
Previous studies on different mouse and human cancer cell lines, like melanoma or breast carcinoma, 
determined the lethal dose (LD90) of IM for these cells to be between 180 and 220 μM after 24h (13). 
Benhadji et al. assessed growth inhibition by MTT assay and calculated the IC50 of colon cancer cell 
lines, finding great variations from 3 μM in Colo-205 cells to more than 300 μM in HCT116 and HCC2998 
cells (30). Overall the concentrations leading to cell death strongly vary depending on the cell line tested 
and our results fit within this range showing most cells reaching a lethal affect at 100 µM IM. In line with 
other reports (16), we found fibroblasts to be relatively resistant to IM while melanoma cells were affected, 
but at higher concentrations than the keratinocytes. In contrast to melanoma cells and fibroblasts, we 
found a biphasic effect on viability and proliferation on keratinocytes and SCC cells. This determines that 
IM induces cell death in two ways, depending on concentration and cell type. Furthermore, our results on 
SCC13 cells indicated that the biphasic effect was IM-specific as compared to another PKC activator, 
TPA. Our microarray performed with various IM concentrations showed the highest number of genes 
differentially expressed at 100 nM, whereas effects were less pronounced at lower and higher 
concentrations, consistent with the impact of 100 nM IM on cell viability and proliferation. This pronounced 
effect at 100 nM again points to the existence of two different concentration-dependent mechanisms of 
action for IM, whereas the highest concentration used leads to cell death due to direct cytotoxicity. The 
lower concentration of 100 nM however, may trigger intracellular pathways that lead to the reduction of 
cell viability. These potential signaling pathways were subject to our further investigations. 
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PKCδ is a key mediator in cell differentiation and inhibition of proliferation in various tissues (31-34). A 
direct binding of IM to PKC isoforms has been observed (22). IM treatment leads to phosphorylation of 
PKCδ in the Colo-205 cancer cell line (30). In other studies, PKCδ was reported to drive keratinocyte 
differentiation and inhibit proliferation of the immortalized keratinocyte line HaCaT, which could be 
reversed by PKCδ inhibition (32). Our data from gene expression to functional experiments in primary cell 
cultures underline a critical role for PKCδ in mediating the effect of IM in keratinocytes and verify such 
previous observations correspondingly for IM while PKCα played only a minor role in our setting.  
 
Downstream of PKC signaling, our pathway analysis revealed an involvement of ERK1/2 in the 
mechanism of action of IM. Previous work on colon cancer cells suggests involvement of MAPK pathways 
including JNK and p38 (30, 35) by showing phosphorylation of these proteins after IM treatment. We 
confirmed activation of ERK1/2 while we were able to exclude a major role of other MAPK pathway 
components like JNK and p38 in keratinocytes and SCC cells. Similar to previous studies on melanoma 
cells (16), our data on keratinocytes clearly link PKCδ to the activation of MAPK signaling. Both MEK and 
ERK are essential for the effect of IM in our assays. Although the activation of the MEK/ERK pathway is 
generally considered to promote tumor cell growth (36), ERK activation seems to contribute favorably to 
the mechanism of action of IM, leading to reduced cell viability and proliferation. In line with this 
assumption, ERK activation was found to suppress tumors by promotion of selective protein degradation 
(37). Moreover, high ERK activation can serve as a marker of improved outcome in breast cancer patients 
(38).  
 
We identified and validated a role for several novel genes as critical players in the mechanism of action of 
IM. Our analysis focused on IL13RA2 and IL1R2, which were both induced by IM in a PKCδ/MEK/ERK-
dependent manner. Both genes encode for interleukin receptors that are commonly known to function as 
decoy receptors without signaling ability (39, 40). Nevertheless, a recent publication attributed an active 
role to IL13RA2 in signaling, thus inducing TGFβ-mediated fibrosis (23). However, to the case for IM 
induced effects, induction of fibrosis is unlikely as patients treated with IM do not show (fibrosis-related) 
scarring and have a good cosmetic outcome post-treatment with IM gel (11). Moreover, a recent study 
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revealed a role of IL13RA2 in tumor suppression, as IL13RA2-overexpressing breast and pancreatic 
cancer cells showed reduced or no tumor growth when injected into mice (24). 
Similarly, IL1R2 recently showed activity against ectopic tissue growth and endometriosis progression and 
could down-regulate the anti-apoptotic protein Bcl2 (41), which could explain that the cell death 
mechanism by IM could be attributed by IL1R2 signaling. As IL1β was shown to promote proliferation of 
oral keratinocytes (25), one could speculate whether IL1R2 is upregulated by IM to capture IL1β and 
prevent this effect. Further studies are needed to clarify the role of IL13RA2 and IL1R2 in the mechanism 
of action of IM. 
 
In summary, we report a mechanism of action for IM in proliferating normal and malignant keratinocytes 
through specific activation of PKCδ leading to activation of MEK/ERK signaling, resulting in decreased 
viability. This was dependent on concentration and cell type, resulting in a unique biphasic induced loss of 
viability through IM. A set of genes responsive to IM treatment, mainly IL13RA2 and IL1R2, showed that 
they partially mediate the function of IM on SCC, suggesting a function for them apart from their role in the 
immune system. However, our data do not allow us to conclude whether IL13RA2 and IL1R2 exert their 
effect primarily in keratinocytes treated by IM or whether they are instrumental in orchestrating the 
accompanying immune response. Further projects are needed to shed more light on this matter. 
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Figure legend 
Figure 1. Ingenol mebutate affects viability and proliferation of keratinocytes and SCC cells. Primary 
keratinocytes and patient-derived SCC cells of three different donors and the human squamous cell 
carcinoma cell lines SCC12 and SCC13 were treated with the indicated concentrations of ingenol 
mebutate for 24h, 48h or 72h. A, cell viability measured by MTT assay B, cell proliferation measured by 
BrdU incorporation. All values were normalized to DMSO-treated cells. Graphs represent mean and 
standard deviation of three independent experiments. 
 
Figure 2. Gene expression analysis of IM-treated primary keratinocytes and patient-derived SCC cells. A, 
Heatmap showing triplicates of differentially expressed genes between DMSO-treated and IM-treated 
primary keratinocytes and patient-derived SCC cells. Cells were treated with either DMSO or 100 nM IM 
for 24h followed by RNA extraction and performance of the microarray. B, Number of differentially 
expressed genes in primary keratinocytes and patient-derived SCC cells after treatment with 100 nM IM. 
Upregulated genes are displayed in red, downregulated genes are displayed in blue. 
 
Figure 3. PKCδ is phosphorylated after IM treatment and is essential for the performance of IM. A, 
Primary keratinocytes and SCC13 cells were treated with 100 nM IM for 10 min, 30 min or 45 min followed 
by protein extraction. Phosphorylation of PKCδ Y311 and PKCα/βII T638/641 was detected by western 
blotting. Total PKCδ or PKCα was used as loading control. B, Primary keratinocytes, patient-derived SCC 
cells and SCC13 cells were treated for 24h with 100 nM IM alone or in combination with the PKC inhibitor 
AEB071  followed by protein extraction. Phosphorylation of PKCδ T505 was detected by western blotting. 
Total PKCδ was used as loading control. C, Primary keratinocytes, patient-derived SCC cells and SCC13 
cells were treated for 24h with 100 nM IM alone or in combination with the PKC inhibitor AEB071 followed 
by assessing cell viability by MTT assay. Graphs represent mean and sd of three independent 
experiments. Data were analyzed by one-way ANOVA followed by Dunnet’s multiple-comparison test. * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. D, SCC13 cells were transfected with two different 
siRNA against PKCδ (left panel) or PKCα (right panel) followed by 24h treatment with 100 nM IM and 
followed by assessing cell viability by MTT assay. Graphs represent mean and SD of three independent 
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experiments. Data were analyzed by Student’s t-test. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001.  
 
Figure 4. ERK is activated by IM treatment in a PKC-dependent manner. A, Phosphorylation of JNK and 
p38 was analyzed in total protein extracts of primary keratinocytes and patient-derived SCC cells after 10 
min and 30 min of IM treatment. B, Immunohistochemical staining for ERK phosphorylation after 24h 
treatment with either vehicle or IM 0.05% in healthy skin organ cultures from three different donors. Scale 
bar = 100 µm. C, ERK target genes are upregulated after 24h of IM treatment and can be blocked by PKC 
inhibition or by knockdown of PKCδ. Gene expression was assessed by qPCR. Graphs represent mean 
and SD of three independent experiments. Data were analyzed by one-way ANOVA followed by Dunnet’s 
multiple-comparison test. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. D, Phosphorylation of 
ERK after IM treatment can be blocked by the PKC inhibitor or by knockdown of PKCδ. Primary 
keratinocytes, patient-derived SCC cells and SCC13 cells were treated for 10 min with IM alone or in 
combination with the PKC inhibitor followed by protein extraction. Moreover, SCC13 cells were transfected 
with two different siRNAs against PKCδ followed by 10 min IM treatment. Extracts were analyzed by 
western blotting and stained for ERK phosphorylation. Total ERK protein was used as loading control. E, 
Immunohistochemical staining of healthy skin for ERK phosphorylation after 18h treatment with either 
vehicle or IM 0.015% alone or in combination with the PKC inhibitor. Pictures show representative 
staining. Left panel: H&E staining, right panel: pERK staining, scale bar = 100 µm. F, Inhibition of PKC, 
MEK or ERK but not JNK or p38 partially rescues viability of IM treated cells. Primary keratinocytes, 
patient-derived SCC cells and SCC13 cells were treated for 24h with either IM alone or in combination 
with the PKC, MEK, ERK, JNK or p38 inhibitor. Viability was assessed by MTT assay. Graphs show mean 
and SD of at least three independent experiments. Data were analyzed by one-way ANOVA followed by 
Dunnett’s multiple comparison test. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
 
Figure 5. IL13RA2 and IL1R2 are involved in the mechanism of action of IM. A, IL13RA2 and IL1R2 gene 
expression is upregulated by IM treatment in a PKC/MEK/ERK -dependent manner. Cells were treated 
either with IM alone or in combination with the indicated kinase inhibitors for 24h followed by RNA isolation 
and gene expression analysis by qPCR. Data of at least three independent experiments were analyzed by 
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one-way ANOVA followed by Dunnett’s multiple comparison test. * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001  . B, IL13RA2 and IL1R2 are PKCδ-dependent. SCC13 cells were transfected with siRNA 
against PKCδ and treated for 24h with 100 nM IM. Cell viability was assessed by MTT assay. C, Knock-
down of IL13AR2 and IL1R2 partially rescues viability of IM treated cells. SCC13 cells were transfected 
with two different siRNA against IL13RA2 or IL1R2 followed by 24h of IM treatment. Viability was 
assessed by MTT assay. All graphs (B, C) show mean and SD of three independent experiments. Data 
were analyzed by Student’s t-test. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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